Subscribe To

Price Alert Latest News Economic Calendar News

THRD / Third Harmonic's stock falls 75% after discontinuing clinical trial

Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatment for chronic inducible urticaria, a common inflammatory skin condition, over safety concerns. Third Harmonic said it plans to provide the full data from the study as well as an update on its corporate strategy in early 2023. Read More

Demo Live Account See Partner Details

Content Topics

Third

Harmonic

Stock

Falls

After

Discontinuing

Clinical

Harmonic s

THRD

Posted: Dec 15 2022, 08:22

Author Name: Market Watch

THRD News

By GlobeNewsWire
August 31, 2023

Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wa

By Benzinga
February 3, 2023

Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

By InvestorPlace
December 15, 2022

Why Is Third Harmonic Bio (THRD) Stock Down 75% Today?

Long-term investors of Third Harmonic Bio (NASDAQ: THRD ) are feeling some discomfort today, to put it mildly. This morning, THRD stock is losing the

By Market Watch
December 15, 2022

Third Harmonic's stock falls 75% after discontinuing clinical trial

Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatm

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.